If your eye doctor mentioned early macular changes and said the word AREDS2, you probably left with a name and not much else. This is what I would tell a patient who had another twenty minutes.
What the AREDS studies actually were
The Age-Related Eye Disease Studies (AREDS and AREDS2) were run by the National Eye Institute, part of the National Institutes of Health. They were large, long-running trials that tested whether specific nutrients, at specific doses, could support macular health as people age.
The second study refined the first: it looked at lutein and zeaxanthin in place of beta-carotene, and at a lower zinc level. Those findings are why “AREDS2” now appears on so many supplement bottles.
Here is the part that matters: the phrase on a label tells you almost nothing. It is not a certification, and nobody polices it. A bottle can say AREDS2 while containing a fraction of the amounts that were studied.
Three things to look for on any label
1. The actual milligrams
Turn the bottle around and read the Supplement Facts panel. Lutein and zeaxanthin should be listed with real numbers next to them. If a product references AREDS2 on the front but the amounts on the back are well below what the trial used, those are two different claims.
2. Whether anything is hidden in a blend
“Proprietary blend” means the manufacturer is telling you what is in the bottle but not how much of each. For a category where dose is the entire point, that should give you pause. Every ingredient should carry its own number.
3. Whether anyone independent has checked
Supplements are not pre-approved by the FDA the way medications are. Third-party testing, done batch by batch, is how you know the contents match the label. Ask whether it is done, and how often.
What to ask at your next appointment
Bring these. They take two minutes, and they are the questions I wish more patients asked.
- Given what you saw in my exam, is nutritional supplementation appropriate for me now, or is it something to revisit later?
- Are there interactions I should think about with my current medications?
- How often should I be re-examined?
- Is there anything besides supplementation I should be doing — diet, sun protection, smoking, blood pressure?
- If I start something, how will we know whether to continue?
Get the full guide
The complete version goes further: what the numbers on a panel mean, how to compare two bottles side by side, and a printable page of questions to bring to your appointment. Enter your email and I will send it.
[Klaviyo embedded sign-up form goes here — single email field]
Why I am the one writing this
I am a practicing retina specialist. I started Pristene because I kept seeing patients take eye supplements that were under-dosed, vague about their contents, or both — and there was no good answer when they asked me what to buy instead.
So we built one. Macutene® Protect is an AREDS2-based formula with more than twice the lutein and zeaxanthin used in that trial, every ingredient printed with its amount, and third-party testing on every batch. You do not need to buy it to use this guide. But you should hold whatever you do buy to the standards above.
— Rama D. Jager, MD, MBA, FACS
Founder, Pristene
Selected research
These are the primary studies discussed above. The links go to the National Library of Medicine (PubMed) and the National Eye Institute — independent, public sources.
- Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8. Archives of Ophthalmology. 2001;119(10):1417–1436. Read on PubMed
- Age-Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial. JAMA. 2013;309(19):2005–2015. Read on PubMed
- Chew EY, Clemons TE, Agrón E, et al. Long-term outcomes of adding lutein/zeaxanthin and omega-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology. 2022;140(7):692–698. Read on PubMed
- National Eye Institute. Age-Related Eye Disease Studies (AREDS/AREDS2): overview and results. Read at nei.nih.gov
Important
This page is general educational information and is not medical advice. It is not a diagnosis and does not replace an examination by your own eye care professional.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Back